The company said it’s taking actions to offset the financial impact next year through increased demand in non-GLP-1 biologics and other high-value products.
The facilities will expand Lonza’s clinical through commercial capabilities in antibody-drug conjugates, viral vectors for cell and gene therapies, and drug delivery.
Private equity firm GI Partners acquired Charles River’s contract development and manufacturing organization business and has formed an independent company.
CEO Greg Behar contends the company is investing in the technologies, capabilities, and expertise needed to remain one of the industry’s leading CDMOs.
Jubilant HollisterStier, KBI Biopharma, and Kindeva are benchmarking XR-based biomanufacturing technician onboarding outcomes versus non-XR training protocols.
Despite being designated as a “Chinese military” company by the U.S. Department of Defense, the CRDMO continues its strong growth in total revenue and net profit.
Building capacity across the radiopharmaceutical value chain is proving to be a significant challenge given the need for specialized facilities, according to the firm.
